Profile data is unavailable for this security.
About the company
PolyNovo Limited is an Australia-based company, which is engaged in the development of medical devices for various medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM product is designed to help surgeons treat traumatic wounds. NovoSorb BTM may be used to temporarily close the wound and aid the body in generating new tissue. It is indicated for full or deep partial-thickness burns, surgical and reconstructive wounds and traumatic wounds. BTM is applied to a wound once the unhealthy or dead tissue has been surgically removed. NovoSorb is a medical-grade polymers that can be expressed in a range of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products.
- Revenue in AUD (TTM)84.68m
- Net income in AUD1.59m
- Incorporated1998
- Employees237.00
- LocationPolynovo Ltd2/320 Lorimer StreetMELBOURNE 3207AustraliaAUS
- Phone+61 80095-8289
- Fax+61 38681-4099
- Websitehttps://polynovo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 385.91m | 1.00 | -- | 8.35 | -- | 1,925.88 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
| Opthea Ltd | 179.52k | -247.75m | 404.31m | 5.00 | -- | -- | -- | 2,252.20 | -0.4748 | -0.4748 | 0.0004 | -0.1085 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
| PYC Therapeutics Ltd | 21.54m | -21.65m | 466.61m | 23.00 | -- | 12.48 | -- | 21.66 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
| Immutep Ltd | 256.62k | -40.50m | 499.31m | 19.00 | -- | 4.32 | -- | 1,945.72 | -0.0394 | -0.0394 | 0.0003 | 0.0973 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
| Mayne Pharma Group Ltd | 278.45m | -258.82m | 596.37m | 900.00 | -- | 1.04 | -- | 2.14 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
| Imugene Ltd | 0.00 | -89.24m | 622.18m | 0.00 | -- | 3.13 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
| Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 744.89m | 16.00 | 25.51 | 4.17 | 23.92 | 8.53 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Clarity Pharmaceuticals Ltd | 0.00 | -30.56m | 1.02bn | -- | -- | 16.21 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
| Mesoblast Ltd | 11.45m | -112.00m | 1.22bn | 83.00 | -- | 1.39 | -- | 106.74 | -0.1358 | -0.1358 | 0.014 | 0.7685 | 0.0112 | -- | 3.71 | 137,899.70 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| Polynovo Ltd | 84.68m | 1.59m | 1.39bn | 237.00 | 873.91 | 20.09 | 352.26 | 16.38 | 0.0023 | 0.0023 | 0.1207 | 0.10 | 0.9084 | 1.01 | 7.28 | 388,440.70 | 1.71 | -9.03 | 1.98 | -10.92 | 94.30 | 93.52 | 1.88 | -10.49 | 4.52 | -0.582 | 0.1817 | -- | 59.53 | 61.65 | -312.95 | -- | 47.35 | -- |
| Neuren Pharmaceuticals Ltd | 237.63m | 157.08m | 2.45bn | -- | 15.69 | 11.90 | 15.59 | 10.31 | 1.22 | 1.22 | 1.84 | 1.61 | 1.63 | -- | 21.92 | -- | 107.87 | 49.80 | 127.30 | 55.37 | -- | -- | 66.10 | 50.10 | -- | -- | 0.00 | 0.00 | 1,403.22 | 76.78 | 85,270.11 | 119.64 | -- | -- |
| Telix Pharmaceuticals Ltd | 502.55m | 5.21m | 4.89bn | 234.00 | 1,047.42 | 32.17 | 409.12 | 9.73 | 0.0141 | 0.0141 | 1.55 | 0.46 | 1.54 | 14.59 | 9.65 | -- | 1.59 | -29.21 | 2.54 | -40.27 | 62.56 | 61.64 | 1.04 | -37.14 | 1.32 | 24.03 | 0.1049 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Polynovo Ltd's reporting currency: Australian Dollar AUD
11.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 21.92m | 3.18% |
| Vanguard Investments Australia Ltd.as of 31 Mar 2024 | 12.11m | 1.75% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 Dec 2023 | 11.65m | 1.69% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 8.61m | 1.25% |
| FIL Investment Management (Hong Kong) Ltd.as of 29 Feb 2024 | 7.92m | 1.15% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.45m | 0.93% |
| Netwealth Investments Ltd.as of 07 Aug 2023 | 4.28m | 0.62% |
| BetaShares Capital Ltd.as of 28 Mar 2024 | 3.92m | 0.57% |
| BlackRock Investment Management (Australia) Ltd.as of 04 Apr 2024 | 2.16m | 0.31% |
| BlackRock Asset Management North Asia Ltd.as of 31 Jan 2024 | 1.81m | 0.26% |
More ▼
Data from 31 Dec 2023 - 24 Apr 2024Source: FactSet Research Systems Inc.
